AR032335A1 - Polimorfos del compuesto triazolo [4,5-d] pirimidina, una mezcla, proceso para su preparacion, composicion farmaceutica, y uso de estos compuestos para la fabricacion de medicamentos - Google Patents

Polimorfos del compuesto triazolo [4,5-d] pirimidina, una mezcla, proceso para su preparacion, composicion farmaceutica, y uso de estos compuestos para la fabricacion de medicamentos

Info

Publication number
AR032335A1
AR032335A1 ARP010102432A ARP010102432A AR032335A1 AR 032335 A1 AR032335 A1 AR 032335A1 AR P010102432 A ARP010102432 A AR P010102432A AR P010102432 A ARP010102432 A AR P010102432A AR 032335 A1 AR032335 A1 AR 032335A1
Authority
AR
Argentina
Prior art keywords
compounds
manufacture
mixture
preparation
pharmaceutical composition
Prior art date
Application number
ARP010102432A
Other languages
English (en)
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9892841&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR032335(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of AR032335A1 publication Critical patent/AR032335A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Surgery (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Polimorfos del compuesto triazolo [4,5-d]pirimidina que tienen la formula (1), en una forma sustancialmente cristalina, una mezcla, proceso para su preparacion, composicion farmacéutica, y uso de estos compuestos para la fabricacion de medicamentos, y en la formulacion de las composiciones de droga, es importante para la sustancia de la droga, que tenga una forma que se pueda manejar y procesar convenientemente. El compuesto de la formula (1) exhibe una elevada potencia como antagonista de P2T (P2YADP o P2TAC), util como antittrombotico, también tiene una estabilidad y biodisponibilidad metabolica sorprendemente elevada.
ARP010102432A 2000-06-02 2001-05-22 Polimorfos del compuesto triazolo [4,5-d] pirimidina, una mezcla, proceso para su preparacion, composicion farmaceutica, y uso de estos compuestos para la fabricacion de medicamentos AR032335A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0013407.2A GB0013407D0 (en) 2000-06-02 2000-06-02 Forms of a chemical compound

Publications (1)

Publication Number Publication Date
AR032335A1 true AR032335A1 (es) 2003-11-05

Family

ID=9892841

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP010102432A AR032335A1 (es) 2000-06-02 2001-05-22 Polimorfos del compuesto triazolo [4,5-d] pirimidina, una mezcla, proceso para su preparacion, composicion farmaceutica, y uso de estos compuestos para la fabricacion de medicamentos
ARP080103205A AR068086A2 (es) 2000-06-02 2008-07-24 Polimorfos del compuesto triazolo (4,5-d) pirimidina , una mezcla , proceso para su preparacion , composicion farmaceutica y uso de estos compuestos para la fabricacion de medicamentos

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP080103205A AR068086A2 (es) 2000-06-02 2008-07-24 Polimorfos del compuesto triazolo (4,5-d) pirimidina , una mezcla , proceso para su preparacion , composicion farmaceutica y uso de estos compuestos para la fabricacion de medicamentos

Country Status (36)

Country Link
US (3) US20030181469A1 (es)
EP (3) EP1289992B1 (es)
JP (3) JP5036947B2 (es)
KR (1) KR100781864B1 (es)
CN (2) CN1247583C (es)
AR (2) AR032335A1 (es)
AT (2) ATE320430T1 (es)
AU (4) AU2001262874B2 (es)
BG (3) BG65837B1 (es)
BR (1) BR0111328A (es)
CA (1) CA2408596C (es)
CY (1) CY1113047T1 (es)
CZ (2) CZ304347B6 (es)
DE (1) DE60117972T2 (es)
DK (2) DK1493745T3 (es)
EE (1) EE05222B1 (es)
ES (2) ES2384708T3 (es)
GB (1) GB0013407D0 (es)
HK (2) HK1052347B (es)
HU (2) HU229374B1 (es)
IL (4) IL152777A0 (es)
IS (2) IS2609B (es)
MX (1) MXPA02011795A (es)
MY (2) MY140674A (es)
NO (3) NO323780B1 (es)
NZ (1) NZ522638A (es)
PH (1) PH12011000127A1 (es)
PL (2) PL359172A1 (es)
PT (2) PT1493745E (es)
RU (3) RU2325391C2 (es)
SG (1) SG135965A1 (es)
SI (2) SI1493745T1 (es)
SK (1) SK287817B6 (es)
UA (1) UA73181C2 (es)
WO (1) WO2001092262A1 (es)
ZA (1) ZA200209324B (es)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI229674B (en) 1998-12-04 2005-03-21 Astra Pharma Prod Novel triazolo[4,5-d]pyrimidine compounds, pharmaceutical composition containing the same, their process for preparation and uses
GB0013407D0 (en) * 2000-06-02 2000-07-26 Astrazeneca Ab Forms of a chemical compound
GB0013488D0 (en) * 2000-06-02 2000-07-26 Astrazeneca Ab Chemical compound
JP4298212B2 (ja) * 2002-03-29 2009-07-15 大日本印刷株式会社 塩酸エピナスチン高融点型結晶の製造法
WO2008024044A1 (en) * 2006-08-21 2008-02-28 Astrazeneca Ab Compositions, suitable for oral administration, comprising a triazolo [4, 5] pyrimidin derivate
TWI482772B (zh) * 2006-08-21 2015-05-01 Astrazeneca Ab 適合口服且包含三唑并[4,5-d]嘧啶衍生物之組合物
US7566722B2 (en) * 2006-10-31 2009-07-28 Janssen Pharmaceutica, N.V. Triazolopyrimidine derivatives as ADP P2Y12 receptor antagonists
EP2591783A1 (en) * 2007-04-13 2013-05-15 Millennium Pharmaceuticals, Inc. Combination anticoagulant therapy with a compound that acts as a factor Xa inhibitor
TWI496776B (zh) * 2007-11-15 2015-08-21 Astrazeneca Ab 製備(3aR,4S,6R,6aS)-6-胺基-2,2-二甲基四氫-3aH-環戊并[d][1,3]二氧雜環戊烯-4-醇之純非對映異構性之二苯甲醯-L-酒石酸鹽之方法
UA100864C2 (uk) 2007-12-03 2013-02-11 Астразенека Аб Спосіб лікування або запобігання аневризмі черевної аорти
ES2558843T3 (es) 2008-09-09 2016-02-09 Astrazeneca Ab Procedimiento para preparar [1S-[1-alfa,2-alfa,3-beta(1S*,2R*),5-beta]]-3-[7-[2-(3,4-difluorofenil)-ciclopropilamino]-5-(propiltio)-3H-1,2,3-triazolo[4,5-d]pirimidin-3-il]-5-(2-hidroxietoxi)ciclopentano-1,2-diol y a sus productos intermedios
EP2459564B1 (en) 2009-07-27 2016-09-07 Auspex Pharmaceuticals, Inc. Cyclopropyl modulators of p2y12 receptor
CA2781182A1 (en) * 2009-12-03 2011-06-09 Astrazeneca Ab Co - crystals of a triazolo [4,5 - d] pyrimidine platelet aggregation inhibitor
EA026094B1 (ru) * 2009-12-23 2017-03-31 Рациофарм Гмбх Твердая лекарственная форма тикагрелора
CZ2011229A3 (cs) * 2011-04-19 2012-08-15 Zentiva, K.S. Opticky aktivní soli (3aR,4S,6R,6aS)-6-amino-2,2-dimethyltetrahydro-3aH-cyklopenta-[d][1,3]dioxol-4-olu a zpusob jejich prípravy
KR20140028011A (ko) 2011-06-01 2014-03-07 아스트라제네카 아베 신규한 티카그렐러 공결정
BR112014013085A2 (pt) * 2011-11-30 2017-06-13 Actavis Group Ptc Ehf forma cristalina do ticagrelor, processo para a preparação da forma cristalina do ticagrelor, composição farmacêutica e processo para preparar uma composição farmacêutica
WO2013150495A2 (en) 2012-04-05 2013-10-10 Dr. Reddy's Laboratories Limited Preparation of ticagrelor
BR112014032085A2 (pt) * 2012-06-29 2017-06-27 Zentiva Ks solvato de ticagrelor, processos para a preparação de um solvato e para a preparação de um cocristal, cocristal de ticagrelor, e, usos de um solvato e de um cocristal
WO2014006091A1 (en) 2012-07-04 2014-01-09 Lek Pharmaceuticals D.D. Ticagrelor adducts with divalent metal salts
CZ2012705A3 (cs) * 2012-10-16 2014-04-23 Zentiva, K.S. Pevná orální farmaceutická formulace obsahující ticagrelor
CN103772393B (zh) * 2012-10-18 2017-08-04 博瑞生物医药（苏州）股份有限公司 替卡格雷的晶型及其制备方法
WO2014083139A1 (en) * 2012-11-29 2014-06-05 Actavis Group Ptc Ehf Novel amorphous form of ticagrelor
CN103848836B (zh) * 2012-12-07 2016-08-03 天津市汉康医药生物技术有限公司 替卡格雷倍半水合物及其制备方法
WO2014118808A2 (en) * 2013-02-04 2014-08-07 Hetero Research Foundation Ticagrelor solid dispersion
CZ307217B6 (cs) 2013-03-14 2018-04-04 Zentiva, K.S. Zlepšený způsob výroby a nové intermediáty syntézy ticagreloru
IN2013MU01111A (es) * 2013-03-25 2015-05-01 Glenmark Generics Ltd
CN104098570A (zh) * 2013-04-07 2014-10-15 杭州领业医药科技有限公司 替卡格雷晶型及其制备方法和用途
CN104098572A (zh) * 2013-04-08 2014-10-15 博瑞生物医药技术(苏州)有限公司 替卡格雷共晶型
CN107573333B (zh) * 2013-04-10 2019-10-18 江苏恒瑞医药股份有限公司 替格瑞洛的中间体及其制备方法和替格瑞洛的制备方法
EP2813216A1 (en) 2013-06-10 2014-12-17 Zentiva, a.s. Stabilized amorphous ticagrelor
WO2014170026A1 (en) 2013-04-18 2014-10-23 Zentiva, K.S. Stabilized amorphous ticagrelor
EA201501164A1 (ru) 2013-05-29 2016-08-31 Рациофарм Гмбх Твердая фармацевтическая лекарственная форма
CN104211704B (zh) * 2013-06-03 2017-08-25 杭州领业医药科技有限公司 结晶形态的三唑[4,5‑d]嘧啶化合物及其制备方法和用途
WO2014195861A2 (en) * 2013-06-04 2014-12-11 Dr. Reddy’S Laboratories Limited Preparation of ticagrelor
EP2816043A1 (en) 2013-06-21 2014-12-24 LEK Pharmaceuticals d.d. Spherical ticagrelor particles
WO2015001489A1 (en) * 2013-07-01 2015-01-08 Ranbaxy Laboratories Limited Pharmaceutical compositions of ticagrelor
CN104341423B (zh) * 2013-08-02 2017-03-01 上海京新生物医药有限公司 替格瑞洛的一水合物及其制备方法与在制药中的应用
CN104370912A (zh) * 2013-08-13 2015-02-25 开原亨泰制药股份有限公司 替卡格雷多晶型体及其制备方法
IN2013CH04023A (es) * 2013-09-10 2015-08-07 Laurus Labs Pvt Ltd
CZ2013866A3 (cs) 2013-11-08 2015-05-20 Zentiva, K.S. Způsob výroby a nová krystalická forma intermediátu syntézy ticagreloru
CN104650085A (zh) * 2013-11-22 2015-05-27 天津市汉康医药生物技术有限公司 替卡格雷倍半水合物化合物
CN103601726B (zh) * 2013-12-02 2016-09-28 浙江大学 两种替格瑞洛药物共晶及其制备方法
CN104710425B (zh) * 2013-12-16 2019-06-14 石药集团中奇制药技术（石家庄）有限公司 一种替格瑞洛新结晶及其制备方法
CN104650091B (zh) * 2014-01-24 2016-10-05 福州乾正药业有限公司 替格瑞洛的微粉化及其晶型，以及制备方法和药物应用
CN104940204A (zh) * 2014-03-27 2015-09-30 广东东阳光药业有限公司 一种替格瑞洛固体制剂及其制备方法
WO2015162537A1 (en) * 2014-04-23 2015-10-29 Glenmark Pharmaceuticals Limited; Glenmark Generics Limited Process for preparation of ticagrelor
WO2015162630A1 (en) 2014-04-25 2015-10-29 Anlon Chemical Research Organization Novel processes for preparing triazolo [4,5-d]- pyrimidines, including ticagrelor, vianew intermediates and new route of synthesis.
CN105315282B (zh) * 2014-07-15 2018-09-21 博瑞生物医药（苏州）股份有限公司 一种制备替卡格雷无定型的方法
WO2016016907A1 (en) * 2014-08-01 2016-02-04 Msn Laboratories Private Limited Novel polymorphs of (1s,2s,3r,5s)-3-[7-{[(1r,2s)-2-(3,4-difluorophenyl) cyclopropyl]amino}-5-(propylthio)-3h-[1,2,3]-triazolo[4,5-d]pyrimidin-3-yi]-5-(2-hydroxvethoxy) cyclopentane-1,2-diol
WO2016024225A1 (en) * 2014-08-11 2016-02-18 Sun Pharmaceutical Industries Limited Stable amorphous ticagrelor and a process for its preparation
CN104193747B (zh) * 2014-08-12 2016-05-11 许彩霞 替卡格雷无定形的制备
WO2016116942A1 (en) 2015-01-20 2016-07-28 Anlon Chemical Research Organization Novel pharmaceutical compounds comprising ticagrelor with salts of aspirin
CN105968113B (zh) * 2015-03-12 2019-06-07 四川海思科制药有限公司 一种三唑并嘧啶衍生物及其应用
WO2017072790A1 (en) * 2015-10-26 2017-05-04 Avra Laboratories Pvt. Ltd. An improved process for synthesis of ticagrelor
US20190002471A1 (en) * 2016-01-05 2019-01-03 Amneal Pharmaceuticals Company Gmbh Crystalline Form Of Ticagrelor
EA201892150A1 (ru) 2016-04-21 2019-05-31 Астразенека Аб Распадающиеся в полости рта таблетки
DK3292867T3 (da) * 2016-09-09 2019-07-22 Univ Liege Ny brug af triazol(4,5-d)pyrimidinderivater til brug i forebyggelsen og behandlingen af bakteriel infektion
US10905691B2 (en) 2016-09-09 2021-02-02 Université de Liège Use of triazolo(4,5-d)pyrimidine derivatives for prevention and treatment of bacterial infection
KR101916956B1 (ko) 2016-12-13 2018-11-08 보령제약 주식회사 티카그렐러의 신규한 고체 형태 및 이의 제조방법
WO2018178997A1 (en) 2017-03-31 2018-10-04 Natco Pharma Limited Novel crystalline form of ticagrelor
WO2019127294A1 (zh) * 2017-12-29 2019-07-04 浙江天宇药业股份有限公司 一种纯化替格瑞洛的方法
WO2019170244A1 (en) 2018-03-08 2019-09-12 Pharmaceutical Oriented Services Ltd. Ticagrelor—containing tablet formulation
WO2020021110A1 (en) 2018-07-27 2020-01-30 Krka, D.D., Novo Mesto Pharmaceutical composition of ticagrelor
CN110194771A (zh) * 2019-05-08 2019-09-03 北京济美堂医药研究有限公司 一种替格瑞洛药用ii晶型的制备方法
CN114634489B (zh) * 2022-04-19 2023-07-04 奎马特里克斯有限公司 结晶形式

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5561134A (en) * 1990-09-25 1996-10-01 Rhone-Poulenc Rorer Pharmaceuticals Inc. Compounds having antihypertensive, cardioprotective, anti-ischemic and antilipolytic properties
EP0840740B1 (en) 1995-07-11 2002-05-02 AstraZeneca AB New inhibitors of platelet aggregation
WO1998028300A1 (en) * 1996-12-20 1998-07-02 Astra Pharmaceuticals Ltd. Triazolo[4,5-d]pyrimidinyl derivatives and their use as medicaments
AR017014A1 (es) * 1997-07-22 2001-08-22 Astrazeneca Ab Compuestos de triazolo [4,5-d]pirimidina, composiciones farmaceuticas, uso de los mismos para preparar medicamentos y procesos para la preparacionde dichos compuestos
EP0998480B1 (en) * 1997-07-25 2002-11-27 Gilead Sciences, Inc. Nucleotide analog composition and synthesis method
TWI229674B (en) * 1998-12-04 2005-03-21 Astra Pharma Prod Novel triazolo[4,5-d]pyrimidine compounds, pharmaceutical composition containing the same, their process for preparation and uses
SE9904129D0 (sv) * 1999-11-15 1999-11-15 Astra Pharma Prod Novel compounds
GB0013488D0 (en) * 2000-06-02 2000-07-26 Astrazeneca Ab Chemical compound
GB0013407D0 (en) * 2000-06-02 2000-07-26 Astrazeneca Ab Forms of a chemical compound

Also Published As

Publication number Publication date
US20030181469A1 (en) 2003-09-25
US7265124B2 (en) 2007-09-04
PL392882A1 (pl) 2011-03-14
US20070293513A1 (en) 2007-12-20
MY140674A (en) 2010-01-15
NO20025756L (no) 2003-01-24
HUP1300386A2 (en) 2003-10-28
WO2001092262A1 (en) 2001-12-06
NO20025756D0 (no) 2002-11-29
RU2005127356A (ru) 2007-03-10
EE200200665A (et) 2004-06-15
JP2014129423A (ja) 2014-07-10
AU2007200958A1 (en) 2007-03-29
KR100781864B1 (ko) 2007-12-05
RU2010150799A (ru) 2012-06-20
SI1289992T1 (sl) 2006-08-31
HK1052347B (zh) 2006-09-08
AR068086A2 (es) 2009-11-04
DE60117972T2 (de) 2006-11-23
CN1817883B (zh) 2011-10-05
NO20120595L (no) 2003-01-24
RU2418802C2 (ru) 2011-05-20
DE60117972D1 (de) 2006-05-11
JP2003535092A (ja) 2003-11-25
BG66332B1 (bg) 2013-06-28
BR0111328A (pt) 2003-06-10
CZ307468B6 (cs) 2018-09-26
SI1493745T1 (sl) 2012-08-31
BG107331A (bg) 2003-07-31
KR20030007829A (ko) 2003-01-23
ES2384708T3 (es) 2012-07-11
ATE555115T1 (de) 2012-05-15
CN1432018A (zh) 2003-07-23
ZA200209324B (en) 2004-02-16
EP1493745A1 (en) 2005-01-05
IS6623A (is) 2002-11-15
DK1493745T3 (da) 2012-07-16
IL152777A0 (en) 2003-06-24
UA73181C2 (en) 2005-06-15
RU2325391C2 (ru) 2008-05-27
JP5036947B2 (ja) 2012-09-26
AU2007200958B2 (en) 2010-10-07
IL202582A (en) 2012-12-31
CN1247583C (zh) 2006-03-29
HK1073101A1 (en) 2005-09-23
IS8825A (is) 2009-06-02
NO332306B1 (no) 2012-08-20
MY148652A (en) 2013-05-15
NO333289B1 (no) 2013-04-29
SK287817B6 (sk) 2011-11-04
GB0013407D0 (en) 2000-07-26
ATE320430T1 (de) 2006-04-15
NO20071547L (no) 2003-01-24
BG65837B1 (bg) 2010-02-26
AU2010257449A1 (en) 2011-01-20
IL152777A (en) 2008-11-26
SG135965A1 (en) 2007-10-29
HK1052347A1 (en) 2003-09-11
CZ304347B6 (cs) 2014-03-19
NO323780B1 (no) 2007-07-02
NZ522638A (en) 2004-06-25
HUP0302284A3 (en) 2007-05-29
HU229374B1 (en) 2013-11-28
PT1289992E (pt) 2006-07-31
HUP0302284A2 (hu) 2003-10-28
EP1493745B2 (en) 2021-05-19
EP1289992A1 (en) 2003-03-12
HU230471B1 (hu) 2016-07-28
PT1493745E (pt) 2012-06-28
IS3019B (is) 2020-02-15
JP2012149093A (ja) 2012-08-09
AU2001262874B2 (en) 2007-03-22
AU6287401A (en) 2001-12-11
CN1817883A (zh) 2006-08-16
DK1289992T3 (da) 2006-07-03
CA2408596C (en) 2010-12-21
SK16852002A3 (sk) 2003-08-05
IL202582A0 (en) 2010-06-30
PL359172A1 (en) 2004-08-23
BG111017A (bg) 2011-12-30
CA2408596A1 (en) 2001-12-06
AU2010257449B2 (en) 2012-03-22
EP2292622A1 (en) 2011-03-09
EP1289992B1 (en) 2006-03-15
EP1493745B1 (en) 2012-04-25
CY1113047T1 (el) 2016-04-13
JP5684192B2 (ja) 2015-03-11
IS2609B (is) 2010-04-15
EE05222B1 (et) 2009-10-15
BG110440A (bg) 2010-03-31
CZ20120293A3 (es) 2003-07-16
US20070173518A1 (en) 2007-07-26
IL187482A (en) 2010-06-16
ES2259031T3 (es) 2006-09-16
PH12011000127A1 (en) 2016-08-31
MXPA02011795A (es) 2003-04-10

Similar Documents

Publication Publication Date Title
AR032335A1 (es) Polimorfos del compuesto triazolo [4,5-d] pirimidina, una mezcla, proceso para su preparacion, composicion farmaceutica, y uso de estos compuestos para la fabricacion de medicamentos
UY29825A1 (es) Derivados sustituidos de 3h-imidazol-(4,5 b (beta))piridina-2-il benzoatos y benzamidas, composiciones farmacéuticas que los contienen y aplicaciones
BRPI0507653A (pt) derivados de imidazopiridina e imidazopiridina formulação farmacêutica compreendendo os mesmos e uso
BRPI0513811A (pt) imidazo [4,5-d] pirimidinas, seus usos e processos de preparação
AR053412A1 (es) Compuestos inhibidores de la interaccion entre mdm2 y p53, un metodo de preparadcion, composicion farmaceutica y uso del compuesto para fabricar medicamentos
AR028833A1 (es) Compuestos inhibidores de metaloproteasas, composiciones farmaceuticas, uso para la manufactura de medicamentos, metodo de tratamiento y procedimiento para su preparacion
WO2006024486A3 (en) Amide derivatives of 3-phenyl dihydropyrimido[4,5-d]pyrimidinones, their manufacture and use as pharmaceutical agents
ECSP10010197A (es) Derivados de piridina y pirazina útiles en el tratamiento de trastornos de proliferación celular
UY28059A1 (es) Nuevos derivados de dihidropirimido (4,5-d) pirimidona sustituida por amino. fabricacion y uso de los mismos como agentes farmaceuticos.
GB0004887D0 (en) Chemical compounds
CR8102A (es) Derivados de pirazolo- quinazolina, procedimiento para preparacion y su uso como inhibidores de quinasa
BRPI0514750A (pt) derivados amida de 7-amino-3-fenil-diidropirimido[4, 5-d]pirimidinonas, sua fabricação e uso como inibidores de proteìna cinase
PE20040999A1 (es) Nuevas pirazolopirimidinas como inhibidores de cinasas dependientes de ciclinas
BRPI0720220B8 (pt) derivado de quinolina, sua composição farmacêutica, seu uso, seu processo de preparação, combinação e produto compreendendo o mesmo
MXPA04002338A (es) Derivados de carbazol y su uso como antagonistas receptores del npy5.
MXPA05011076A (es) Derivados de quinazolina para el tratamiento de cancer.
RU2008145714A (ru) Пуриновые производные в качестве активатора аденозинового рецептора
WO2005118579A3 (en) Thiazole derivatives as chemokine receptor antagonists
AR054508A1 (es) Compuesto de bencilpiperazina, su uso para preparar un medicamento, procedimientos para la preparacion de dicho compuesto y de compuestos intermediarios, dichos compuestos intermediarios, composicion farmaceutica que lo comprende y procedimiento para prepararla
BRPI0607811A2 (pt) derivados de óxido de pirimidina de 2-(4-cianofenilamino) inibidores de hiv, composição farmacêutica compreendendo os mesmo, processo para preparar a referida composição e uso
TW200800984A (en) New compounds
TW200505452A (en) Chemical compounds
UA89795C2 (ru) Фармацевтическая композиция, которая содержит эстер темозоломида
TW200616635A (en) Novel compounds
SE0401655D0 (sv) New compounds

Legal Events

Date Code Title Description
FB Suspension of granting procedure